Table 4.

Characteristics of the Optimized Formulations.^a

Formulation	Size, nm	PDI	ζ Potential, mV	EE, %
PPLNs	193.4 ± 4.204	0.087 ± 0.017	23.6 ± 1.77	35.06 ± 5.703
eTmab-PPLNs	217.4 ± 13.36	0.116 ± 0.057	0.056 ± 0.115	31.27 ± 3.215

Abbreviations: EE, encapsulation efficiency; eTmab-PPLNs, electrostatically conjugated trastuzumab-bearing PPLNs; PDI, polydispersity index; PPLNs, poly (d, l-lactide-co-glycolide)/polyethylenimine/lipid nanoparticles; SD, standard deviation.

^a Data are represented as mean ± SD (n = 3).